只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 交易日 / 申报日 | 公司 | 申报人 | 类型 | 股数 | 每股价格 | 派生金额 | 持有后股数 | 原始申报 |
|---|---|---|---|---|---|---|---|---|
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 231 | US$50.05 | US$11,562.52 | 29,769 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 459 | US$51.55 | US$23,659.89 | 29,310 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 2,063 | US$52.39 | US$108,084.90 | 27,247 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 2,184 | US$53.42 | US$116,669.06 | 25,063 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 63 | US$53.92 | US$3,397.01 | 25,000 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 324 | US$49.97 | US$16,190.77 | 51,748 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 369 | US$51.48 | US$18,996.97 | 51,379 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 2,564 | US$52.32 | US$134,143.35 | 48,815 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 2,638 | US$53.38 | US$140,823.04 | 46,177 | SEC |
| 2026-07-17 2026-07-21 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 123 | US$53.87 | US$6,626.21 | 46,054 | SEC |
| 2026-07-06 2026-07-08 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne Director | 卖出（S） | 4,111 | US$49.98 | US$205,481.76 | 47,773 | SEC |
| 2026-07-06 2026-07-08 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne Director | 卖出（S） | 5,889 | US$50.84 | US$299,421.49 | 41,884 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 24,846 | US$45.38 | US$112.75万 | 220,882 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 24,846 | US$45.38 | US$112.75万 | 220,882 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 24,846 | US$45.38 | US$112.75万 | 220,882 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 46,776 | US$45.00 | US$210.49万 | 6,555,102 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 46,776 | US$45.00 | US$210.49万 | 6,555,102 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 46,776 | US$45.00 | US$210.49万 | 6,555,102 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 787,024 | US$45.38 | US$3571.51万 | 6,601,878 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 787,024 | US$45.38 | US$3571.51万 | 6,601,878 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 787,024 | US$45.38 | US$3571.51万 | 6,601,878 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 1,477 | US$45.00 | US$66,465.00 | 219,405 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 1,477 | US$45.00 | US$66,465.00 | 219,405 | SEC |
| 2026-06-22 2026-06-24 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 1,477 | US$45.00 | US$66,465.00 | 219,405 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 1,268 | US$42.83 | US$54,308.44 | 28,732 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 2,599 | US$43.87 | US$114,018.13 | 26,133 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 1,133 | US$44.74 | US$50,690.42 | 25,000 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 1,238 | US$44.75 | US$55,400.50 | 51,000 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 3,401 | US$43.86 | US$149,167.86 | 52,238 | SEC |
| 2026-06-17 2026-06-22 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin Officer · CHIEF FINANCIAL OFFICER | 卖出（S） | 1,379 | US$42.79 | US$59,007.41 | 55,639 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 9,086 | US$45.02 | US$409,051.72 | 245,728 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 9,086 | US$45.02 | US$409,051.72 | 245,728 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 9,086 | US$45.02 | US$409,051.72 | 245,728 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC TenPercentOwner | 卖出（S） | 272,322 | US$45.02 | US$1225.99万 | 7,388,902 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | OrbiMed Capital GP VII LLC TenPercentOwner | 卖出（S） | 272,322 | US$45.02 | US$1225.99万 | 7,388,902 | SEC |
| 2026-06-15 2026-06-17 | ELVN Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC TenPercentOwner | 卖出（S） | 272,322 | US$45.02 | US$1225.99万 | 7,388,902 | SEC |
| 2026-06-05 2026-06-09 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne Director | 卖出（S） | 354 | US$35.82 | US$12,680.28 | 51,884 | SEC |
| 2026-06-05 2026-06-09 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne Director | 卖出（S） | 7,779 | US$34.28 | US$266,664.12 | 54,105 | SEC |
| 2026-06-05 2026-06-09 | ELVN Enliven Therapeutics, Inc. | Kunkel Lori Anne Director | 卖出（S） | 1,867 | US$35.36 | US$66,017.12 | 52,238 | SEC |
| 2026-05-18 2026-05-20 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 1,302 | US$40.25 | US$52,405.50 | 25,223 | SEC |
| 2026-05-18 2026-05-20 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 3,475 | US$39.53 | US$137,366.75 | 26,525 | SEC |
| 2026-05-18 2026-05-20 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 223 | US$41.21 | US$9,189.83 | 25,000 | SEC |
| 2026-04-17 2026-04-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 2,441 | US$48.06 | US$117,314.46 | 25,000 | SEC |
| 2026-04-17 2026-04-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 140 | US$45.81 | US$6,413.40 | 29,860 | SEC |
| 2026-04-17 2026-04-21 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise Officer · CHIEF MEDICAL OFFICER | 卖出（S） | 2,419 | US$47.39 | US$114,636.41 | 27,441 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| ELVN | 157,861.6632 | 0 | 279,927.5393 | 56.39% | B, Q, N |